Live Breaking News & Updates on Rates Greater Than

Stay updated with breaking news from Rates greater than. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo Trial

A topical formulation of the JAK inhibitor ruxolitinib produced statistically significant improvement in all primary and secondary outcomes relative to vehicle alone at 24 weeks. ....

United States , Tufts Medical Center , Pp David Rosmarin , Iltefat Hamzavi , European Academy Of Dermatology , Drug Administration , Department Of Dermatology , Incyte Corporation , European Academy , Vitiligo Scoring Index , Rates Greater Than , Week Data Might Show More , Henry Ford Hospital , Clinical Research , Clinical Trials , Linical Studies , Us Food And Drug Administration , Nited States Food And Drug Administration , Drug Development ,